Clinical Trial Update: Tace With Icaritin in First-line Treatment of Middle and Advanced HCC in Child Grade B Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating Tace with Icaritin as first-line treatment for middle and advanced hepatocellular carcinoma in Child-Pugh B patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Icaritin (icaritin)
• TACE

Snippet

Sponsor: Henan Cancer Hospital | Conditions: HCC | Phase 2 | Status: UNKNOWN